Cogent Biosciences, Inc. Preferred Stock Dividends, Income Statement Impact
Cogent Biosciences, Inc. (COGT) reported Preferred Stock Dividends, Income Statement Impact of $104.40 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2022-03-15
- Cogent Biosciences, Inc. preferred stock dividends, income statement impact for fiscal 2020 was $104.40M.
| Period end | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|
| 2020-12-31 | $104.40M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |